(Q28168652)

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Efficacy and safety of low-carbohydrate diets: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Therapeutic lifestyle change and Adult Treatment Panel III: evidence then and now.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

A low-carbohydrate as compared with a low-fat diet in severe obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

A randomized trial of a low-carbohydrate diet for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

A randomized trial comparing a very low carbohydrate diet and a calorie-restricted low fat diet on body weight and cardiovascular risk factors in healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Improvement in medical risk factors and quality of life in women and men with coronary artery disease in the Multicenter Lifestyle Demonstration Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Successful weight loss maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Prevalence of impaired glucose tolerance among children and adolescents with marked obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Improved carbohydrate metabolism after physical training and dietary intervention in individuals with the "atherothrombogenic syndrome'. Oslo Diet and Exercise Study (ODES). A randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Effects of weight loss vs aerobic exercise training on risk factors for coronary disease in healthy, obese, middle-aged and older men. A randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Long-term cholesterol-lowering effects of 4 fat-restricted diets in hypercholesterolemic and combined hyperlipidemic men. The Dietary Alternatives Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Change in alpha1 HDL concentration predicts progression in coronary artery stenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Effect of Weight Loss without Salt Restriction on the Reduction of Blood Pressure in Overweight Hypertensive Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Body mass index and the prevalence of hypertension and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Body weight, weight change, and risk for hypertension in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Insulin and blood pressure during weight loss in obese adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Effects of exercise and weight loss on cardiac risk factors associated with syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Risk stratification of obesity as a coronary risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

High triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Prevalence of hyperinsulinaemia in patients with high blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

A constellation of cardiovascular risk factors is associated with hepatic enzyme elevation in hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Hepatic effects of dietary weight loss in morbidly obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

"Buffalo hump" in men with HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Leptin-replacement therapy for lipodystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213

Are health care professionals advising obese patients to lose weight?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.213